title: New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors.
abstract: The treatment of migraine was advanced dramatically with the introduction of triptans in the early 1990s. Despite the substantial improvement in the quality of life that triptans have brought to many migraineurs, a substantial cohort of patients remain highly disabled by attacks and need new therapeutic approaches, which ideally should be quick-acting, have no vasoconstrictor activity, and have a longer duration of action and be better tolerated than current therapies. The calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)-olcegepant (BIBN 4096 BS), telcagepant (MK-0974), MK3207, and BI 44370 TA-are effective in treating acute migraine. They have no vasoconstrictive properties, fewer adverse effects, and may act longer than triptans. Their development has been complicated by liver toxicity issues when used as preventives. Results from studies with BI 44370 TA do not support broad concern about a class effect, and further studies are ongoing in this respect. Many experimental studies and clinical trials suggest that nitric oxide may have a role in the pathophysiology of migraine. Therefore, the inhibition of nitric oxide synthase (NOS) for the acute or prophylactic treatment of migraine offered a feasible approach; as inducible NOS (iNOS) is involved in several pain states, such as inflammatory pain, it appeared to be an attractive target. However, despite high selectivity and potency, the iNOS inhibitor GW274150 was not effective for acute treatment or prophylaxis of migraine, suggesting that iNOS is very unlikely to be a promising target.
authors.affiliation: Department of Neurology, University of California, San Francisco, 1701 Divisadero Street, Suite 480, San Francisco, CA, 94115, USA.
authors.forename: Jan
authors.initials: J
authors.lastname: Hoffmann
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Goadsby
references.citation: J Cereb Blood Flow Metab. 2002 May;22(5):620-9
references.pmid: 11973435
references.citation: Ann Neurol. 1993 Jan;33(1):48-56
references.pmid: 8388188
references.citation: J Biol Chem. 1996 May 10;271(19):11325-9
references.pmid: 8626685
references.citation: Pain. 2001 May;92(1-2):101-6
references.pmid: 11323131
references.citation: Trends Mol Med. 2007 Jan;13(1):39-44
references.pmid: 17141570
references.citation: Endocr Rev. 1996 Oct;17(5):533-85
references.pmid: 8897024
references.citation: Cephalalgia. 2011 Apr;31(5):573-84
references.pmid: 21172952
references.citation: Ann Neurol. 1988 Feb;23(2):193-6
references.pmid: 2454066
references.citation: Peptides. 1998;19(7):1213-25
references.pmid: 9786171
references.citation: Cephalalgia. 2010 Oct;30(10):1159-69
references.pmid: 20855361
references.citation: Cephalalgia. 2005 Mar;25(3):225-36
references.pmid: 15689199
references.citation: Nat Rev Neurol. 2010 Oct;6(10):573-82
references.pmid: 20820195
references.citation: Semin Neurol. 2010 Apr;30(2):107-19
references.pmid: 20352581
references.citation: Neurology. 2008 Apr 15;70(16):1304-12
references.pmid: 17914062
references.citation: J Neurol Sci. 1996 Jun;138(1-2):60-5
references.pmid: 8791240
references.citation: Lancet. 2008 Dec 20;372(9656):2115-23
references.pmid: 19036425
references.citation: Headache. 1998 Jul-Aug;38(7):497-506
references.pmid: 15613165
references.citation: Ann Neurol. 1990 Aug;28(2):183-7
references.pmid: 1699472
references.citation: Ann N Y Acad Sci. 1992 Jun 30;657:119-34
references.pmid: 1637079
references.citation: Neuroscience. 2003;120(3):677-94
references.pmid: 12895509
references.citation: Cephalalgia. 2010 Oct;30(10):1157-8
references.pmid: 20855360
references.citation: Neuroscience. 2010 Aug 25;169(2):683-96
references.pmid: 20472035
references.citation: Nature. 1998 May 28;393(6683):333-9
references.pmid: 9620797
references.citation: Nature. 1982 Jul 15;298(5871):240-4
references.pmid: 6283379
references.citation: Br J Pharmacol. 2004 Aug;142(7):1171-81
references.pmid: 15237097
references.citation: Cephalalgia. 2010 Oct;30(10):1170-8
references.pmid: 20855362
references.citation: N Engl J Med. 2004 Mar 11;350(11):1104-10
references.pmid: 15014183
references.citation: Neurology. 2010 Sep 21;75(12):1098-103
references.pmid: 20855853
references.citation: Arch Neurol. 2000 Mar;57(3):418-20
references.pmid: 10714674
references.citation: Cephalalgia. 2007 Mar;27(3):193-210
references.pmid: 17381554
references.citation: Neurosci Biobehav Rev. 1997 Sep;21(5):649-78
references.pmid: 9353797
references.citation: Brain. 2009 Jan;132(Pt 1):6-7
references.pmid: 19098031
references.citation: Cephalalgia. 1999 Jul;19(6):581-8; discussion 542
references.pmid: 10448545
references.citation: Lancet. 2001 Nov 17;358(9294):1668-75
references.pmid: 11728541
references.citation: Neurol Clin. 1996 May;14(2):421-34
references.pmid: 8827180
references.citation: Cephalalgia. 2002 Feb;22(1):54-61
references.pmid: 11993614
references.citation: J Auton Nerv Syst. 1999 May 28;76(2-3):176-83
references.pmid: 10412842
references.citation: Trends Pharmacol Sci. 1994 May;15(5):149-53
references.pmid: 7538702
references.citation: J Clin Epidemiol. 1991;44(11):1147-57
references.pmid: 1941010
references.citation: Neurology. 2002 Mar 26;58(6):885-94
references.pmid: 11914403
references.citation: Eur Neurol. 1999;41(2):88-93
references.pmid: 10023111
references.citation: Ther Adv Neurol Disord. 2010 Nov;3(6):369-78
references.pmid: 21179597